Led by co-founders Andrew Raslan and Keyvan Jodeiri, Pipeline Organics is developing microbial fuel cells to help food and beverage manufacturers treat wastewater and recover energy as electricity.
Updated
November 16, 2026 12:32 PM

Concept visualisation of Pipeline Organics’ planned TankArc wastewater treatment and energy recovery system at a brewery. IMAGE: PIPELINE ORGANICS
A glass of beer or a bottle of soft drink leaves plenty behind before it reaches the shelf. Producing it requires water and electricity, then creates wastewater that manufacturers must pay to treat. For breweries and other food and beverage manufacturers working with tight margins, those bills can leave less money for new equipment, products and people.
Pipeline Organics, led by Andrew Raslan (commercial) and Dr Keyvan Jodeiri (technology), sees a resource in that waste. The Nottingham-based cleantech startup, Pipeline Organics, is developing microbial fuel cells that treat food and beverage wastewater while generating electricity. The aim is to help factories lower their operating costs by recovering value from a stream they already produce every day.
Founded in August 2021, Pipeline Organics grew out of the University of Nottingham’s Young Entrepreneurs Scheme, YES20. The founding team won its Engineering, Energy and Environment stream before establishing the company. Andrew, now CEO, brought a background in molecular microbiology and antimicrobial research, later moving into project management and commercialization.
Co-founder and chief scientific officer Keyvan Jodeiri brought a different piece of the puzzle. His research explored biofuel cells that could use sugars in blood to generate electricity for medical implants. The team began asking whether related principles could work outside the body, using organic material in industrial wastewater as fuel. Turning that idea into a business meant finding an application where the environmental benefits came with a clear financial incentive.
Food and beverage manufacturing offered that opportunity. Breweries and other food and beverage manufacturers produce wastewater rich in biodegradable organic material such as leftover carbs and fats or dead proteins, making it suitable food for microorganisms. Treating it at the factory also gives the company a more predictable waste stream than the mixture arriving at a general sewage treatment plant.
“What is filthy for you as a manufacturer is food for the bacteria,” Andrew explains.

The company’s system, TankArc, contains reactors with specially designed, 3D-printed lattices. Microorganisms growing on the anode break down organic material in wastewater, releasing electrons that electrodes capture as electrical current. This reduces the organic pollution load while recovering some of its energy. Reactors can be grouped into racks or, eventually, containers equipped with plumbing, batteries and controls to serve different factory sizes.
Andrew describes the system as being designed to become self-powering, provided its electricity output scales as expected, with surplus energy available for use on site. At the moment, replacing a brewery’s entire electricity supply is beyond the immediate promise, Andrew admits. The more practical proposition is reducing the amount of power a manufacturer needs to buy through site efficiency upgrades, while cutting its wastewater treatment burden.
The treated wastewater would then go into the sewer for further treatment. Since it contains fewer pollutants, manufacturers could pay less in treatment charges or, in some cases, avoid them altogether. Pipeline Organics is also exploring ways to take the process further by working with partners to make water reuse possible. This could allow manufacturers to reuse the treated water for tasks that do not require high-purity water, such as post-production washing, which accounts for a large share of fresh-water use in the industry.
Much of TankArc’s engineering sits in the lattice itself. It needs sufficient surface area for the biological process while allowing wastewater to flow through without clogging. Different waste streams require different designs. Pipeline Organics combines engineering calculations with proprietary AI-assisted algorithms to adapt the geometry for applications such as beer, wine or fruit juice production.

Andrew sees this design process as a competitive advantage. Once the geometry has been developed, components can be manufactured from the resulting 3D models. The difficult part is knowing how to design a cell that performs in a particular environment.
The company is competing with established wastewater treatment and energy recovery methods. Anaerobic digestion, for example, produces biogas that can subsequently generate heat and electricity. Pipeline Organics is pursuing direct electricity recovery through compact, modular equipment. Its suitability will depend on the site, the wastewater and the savings it can deliver.
Early brewery trials have helped the team test those assumptions. At Little Ox Brewery, Pipeline Organics used a compact four-reactor system with real wastewater to assess compatibility and electrical output. The trial also provided practical lessons about monitoring, handling and operating equipment around a working production site. The company is working with Castle Rock Brewery in Nottingham as another development partner and have achieved onsite results that are close to commercial readiness.
These demonstrations represent an early step towards industrial deployment. During our interview, Andrew said Pipeline Organics had begun selling paid feasibility pilots that measure performance using customers’ wastewater under actual operating conditions. Larger reactor racks would be at the next stage, followed by containerised systems for facilities producing much greater volumes of effluent. They expect to deploy full-scale containers in 2027.
Scaling brings another set of challenges. The team is developing repeatable methods for producing conductive electrodes, maintaining wastewater flow and assembling larger systems. Reducing manufacturing costs while maintaining treatment performance is a central part of this work.

There will also be useful discoveries along the way: Chief Scientific Officer Keyvan says longer-term ambitions include developing the technology for wastewater sensing and exploring how recovered electricity could support electrochemical production of higher-value chemicals. These could open additional applications for the platform, while the immediate priority remains manufacturing and scaling the wastewater treatment system.
The proposed leasing model reflects the focus on customer economics. Manufacturers would rent equipment rather than purchase it upfront, retaining part of the savings after paying Pipeline Organics. Making that arrangement attractive requires dependable treatment, manageable maintenance and savings that hold up over time.
Andrew’s and Keyvan’s longer-term vision includes a wider portfolio of environmental technologies. For now, the next test is closer to the brewery floor: can the company turn promising small reactors into equipment food and beverage manufacturers can rely on?
“One man’s waste is another man’s raw material if you’re smart about it,” Andrew says. Pipeline Organics is building its business around that possibility, starting with the water left behind by a drink.
Keep Reading
From AI diagnostics to exoskeletons, the event highlights how healthcare tech is moving into real-world use
Updated
May 1, 2026 2:25 PM

Tesla Bot Optimus, designed by Tesla. PHOTO: ADOBE STOCK
The China International Medical Equipment Fair 2026 will open in Shanghai from April 9 to 12 at the National Exhibition and Convention Center. It is one of the largest gatherings in the medical device industry. This year’s edition will cover more than 320,000 square metres. Nearly 5,000 companies and brands are expected to participate, representing over 20 countries and regions. Organisers also expect more than 200,000 professional visitors and buyers from around 150 markets.
A key focus this year is the growing use of artificial intelligence in healthcare. One of the headline technologies is an AI agent designed to carry out multiple diagnoses from a single scan. The exhibition will also feature diagnostic software that is already in clinical use. In addition, an integrated platform for AI training and inference will be showcased to improve computing capacity within healthcare institutions.
Robotics will also play a central role at the event. New systems across surgical procedures, rehabilitation and elderly care are expected to be presented. Together, these developments point to a steady move toward more precise and assisted forms of care. Many of these technologies are designed to support clinicians and patients, especially in tasks that require consistent accuracy or long-term physical assistance.
For the first time, the event will introduce a dedicated Future Tech Arena. It will focus on brain-computer interfaces, embodied intelligence and university-led innovation. The space will include AI-assisted MRI systems for Alzheimer’s diagnosis. It will also feature brain-computer interface technologies used for cognitive assessment and training, along with wearable robotic exoskeletons.
Alongside product showcases, the event will continue to act as a platform for international trade and collaboration. An International Zone will host exhibitors from countries such as the United States, Germany, Japan, South Korea, the United Kingdom, France, Singapore, Malaysia and Thailand. This provides a view of how different markets are approaching medical technology. It also reflects the global nature of innovation and deployment in this sector.
The programme will include a set of networking and exchange formats under its “We” initiative. These include discussion stages with representatives from consulates and industry organisations, as well as matchmaking sessions based on verified buyer demand. Guided tours will also be organised to help international visitors connect with relevant exhibitors. In parallel, organisers are working with hospital partners to provide medical support services for attendees during the event.
Across the four days, hundreds of forums are scheduled. These will bring together policymakers, researchers and industry leaders to discuss regulatory frameworks, market access and the future of healthcare innovation. Some of these sessions will be led by the Global Harmonization Working Party in collaboration with the Ministry of Health of Malaysia, with a focus on regulatory alignment and cross-border cooperation in medical devices.
As healthcare systems continue to adopt digital tools and advanced equipment, events like CMEF provide a clear view of how these technologies are being developed and applied. The scale of participation this year reflects continued activity across both innovation and international collaboration in the medical device sector.